{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:37:19Z","timestamp":1792103839237,"version":"4.4.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010804","name":"Faculty of Medicine, Prince of Songkla University","doi-asserted-by":"publisher","award":["none"],"award-info":[{"award-number":["none"]}],"id":[{"id":"10.13039\/501100010804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Chronic hepatitis B virus (HBV) infection remains a major global health burden and a leading cause of hepatocellular carcinoma (HCC). While cirrhosis is a well-established risk factor, the contributions of metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiometabolic risk factors (CMRFs) are less clearly defined. This study aimed to evaluate the impact of MASLD and CMRFs on HCC risk in patients with chronic hepatitis B (CHB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of CHB patients at Songklanagarind Hospital between 2011 and 2021, excluding those diagnosed with HCC within six months of follow-up. Clinical and imaging data were analyzed. Cumulative HCC incidence was estimated using Nelson-Aalen plots. Multivariable Cox regression was used to identify independent predictors. The aMAP score was evaluated in subgroups with obesity, CMRFs, and MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 4,944 patients, 151 (3.1%) developed HCC. Cirrhosis (adjusted hazard ratio [aHR] 7.22), obesity (aHR 1.85), and male sex (aHR 1.78) were independent risk factors. Statin use (aHR 0.43), higher platelet count (aHR 0.62), and higher albumin (aHR 0.64) were protective. Diabetes and hypertension showed nonsignificant trends, and steatosis and dyslipidemia without statins were not significantly associated with HCC. Risk increased with the number of CMRFs. The aMAP score showed good discrimination in patients with obesity (C-index 0.82), CMRFs (0.79), MASLD (0.74), and in the non-cirrhotic MASLD and non-MASLD (0.69 and 0.71, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cirrhosis, male sex, and obesity were key HCC risk factors. The aMAP score effectively stratified HCC risk among metabolically at-risk CHB patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0341366","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:27:55Z","timestamp":1769192875000},"page":"e0341366","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of cardiometabolic risk factors on hepatocellular carcinoma incidence in patients with chronic hepatitis B: A retrospective cohort study"],"prefix":"10.1371","volume":"21","author":[{"given":"Chanavee","family":"Toh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kedsiree","family":"Sanit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimsiri","family":"Sripongpun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naichaya","family":"Chamroonkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suthat","family":"Liangpunsakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerha","family":"Piratvisuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4058-5977","authenticated-orcid":true,"given":"Apichat","family":"Kaewdech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"pone.0341366.ref001","author":"Global hepatitis report 2024: action for access in low- and middle-income countries"},{"issue":"3","key":"pone.0341366.ref002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"F Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"pone.0341366.ref003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/v17010034","article-title":"Asian perspective on hepatitis B virus and hepatitis C virus elimination","volume":"17","author":"A Kaewdech","year":"2025","journal-title":"Viruses"},{"issue":"1","key":"pone.0341366.ref004","doi-asserted-by":"crossref","first-page":"19544","DOI":"10.1038\/s41598-024-70526-z","article-title":"Changes in the epidemiological trends of primary liver cancer in the Asia-Pacific region","volume":"14","author":"P Danpanichkul","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0341366.ref005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3350\/cmh.2022.0342","article-title":"Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection","volume":"29","author":"C-L Lin","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"pone.0341366.ref006","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/ijms23010500","article-title":"Hepatocellular carcinoma in chronic viral hepatitis: where do we stand?","volume":"23","author":"FP Russo","year":"2022","journal-title":"Int J Molecular Sci"},{"issue":"24","key":"pone.0341366.ref007","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.3390\/cancers14246234","article-title":"Metabolic risk factors for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A prospective study","volume":"14","author":"SO Antwi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0341366.ref008","first-page":"62","article-title":"Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide","volume":"24","author":"DY Kim","year":"2024","journal-title":"J Liver Cancer"},{"key":"pone.0341366.ref009","first-page":"5202684","article-title":"Diabetes mellitus and risk of hepatocellular carcinoma","volume":"2017","author":"X Li","year":"2017","journal-title":"Biomed Res Int"},{"key":"pone.0341366.ref010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/CMAR.S188238","article-title":"Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: A meta-analysis and systematic review","volume":"11","author":"Y Tan","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"2","key":"pone.0341366.ref011","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/hep.30857","article-title":"Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B","volume":"71","author":"HSJ Choi","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"pone.0341366.ref012","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","volume":"67","author":"J-G Fan","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0341366.ref013","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3892\/etm.2024.12387","article-title":"Effect of metabolic dysfunction\u2011associated fatty liver disease on the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta\u2011analysis","volume":"27","author":"S Shen","year":"2024","journal-title":"Exp Ther Med"},{"key":"pone.0341366.ref014","doi-asserted-by":"crossref","first-page":"1178636120918878","DOI":"10.1177\/1178636120918878","article-title":"Presence of Hepatic steatosis does not increase the risk of hepatocellular carcinoma in patients with chronic hepatitis B over long follow-up","volume":"13","author":"CT Lim","year":"2020","journal-title":"Microbiol Insights"},{"issue":"3","key":"pone.0341366.ref015","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/jgh.13536","article-title":"Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B","volume":"32","author":"AWH Chan","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"pone.0341366.ref016","article-title":"Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: A large cohort study","volume":"153","author":"M-W Yu","year":"2017","journal-title":"Gastroenterology"},{"issue":"4","key":"pone.0341366.ref017","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"G Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0341366.ref018","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"R Fan","year":"2020","journal-title":"J Hepatol"},{"key":"pone.0341366.ref019","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/v14050986","article-title":"Hepatitis B virus-associated hepatocellular carcinoma","volume":"14","author":"GEM Rizzo","year":"2022","journal-title":"Viruses"},{"issue":"6","key":"pone.0341366.ref020","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"PK Whelton","year":"2018","journal-title":"Hypertension"},{"key":"pone.0341366.ref021","article-title":"Diagnosis and classification of diabetes: Standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"pone.0341366.ref022","article-title":"Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease","author":"National Clinical Guideline Centre (UK)","year":"2014","journal-title":"London: National Institute for Health and Care Excellence (UK)"},{"key":"pone.0341366.ref023","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"Consultation WHO Expert","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"pone.0341366.ref024","doi-asserted-by":"crossref","first-page":"13961","DOI":"10.1038\/s41598-024-64988-4","article-title":"Effect of smartphone-assisted lifestyle intervention in MASLD patients: A randomized controlled trial","volume":"14","author":"A Kaewdech","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"pone.0341366.ref025","first-page":"100658","article-title":"The imaging techniques and diagnostic performance of ultrasound, CT, and MRI in detecting liver steatosis and fat quantification: A systematic review","volume":"16","author":"Y Wan","year":"2023","journal-title":"J Radiation Res Appl Sci"},{"key":"pone.0341366.ref026","first-page":"101133","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"ME Rinella","year":"2023","journal-title":"Ann Hepatol"},{"issue":"6","key":"pone.0341366.ref027","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"ME Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0341366.ref028","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"ME Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"pone.0341366.ref029","doi-asserted-by":"crossref","first-page":"234","DOI":"10.33192\/smj.v76i4.267556","article-title":"Navigating the nomenclature of liver steatosis: Transitioning from NAFLD to MAFLD and MASLD - understanding affinities and differences","volume":"76","author":"A Kaewdech","year":"2024","journal-title":"Siriraj Med J"},{"issue":"3","key":"pone.0341366.ref030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/gut.2005.069153","article-title":"Diagnosis of cirrhosis by transient elastography (FibroScan): A prospective study","volume":"55","author":"J Foucher","year":"2006","journal-title":"Gut"},{"key":"pone.0341366.ref031","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","author":"AG Singal","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"pone.0341366.ref032","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Liver European Association for the Study of the","year":"2025","journal-title":"J Hepatol"},{"issue":"13","key":"pone.0341366.ref033","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/diagnostics14131325","article-title":"Clinical utility of the aMAP score for predicting hepatocellular carcinoma development in patients with chronic hepatitis B","volume":"14","author":"S Chaiwiriyawong","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"18","key":"pone.0341366.ref034","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e37990","article-title":"Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma","volume":"10","author":"G Adali","year":"2024","journal-title":"Heliyon"},{"key":"pone.0341366.ref035","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/9781119436812.ch59","article-title":"Epidemiology of Hepatocellular Carcinoma","author":"HB El\u2010Serag","year":"2020","journal-title":"The Liver. Wiley"},{"issue":"2","key":"pone.0341366.ref036","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.cgh.2017.08.042","article-title":"Role of age and race in the risk of hepatocellular carcinoma in veterans with hepatitis B virus infection","volume":"16","author":"S Mittal","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"pone.0341366.ref037","doi-asserted-by":"crossref","first-page":"101713","DOI":"10.1016\/j.clinre.2021.101713","article-title":"Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: A prospective cohort study","volume":"45","author":"L Lam","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"pone.0341366.ref038","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.30973","article-title":"Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"71","author":"MJ Goh","year":"2020","journal-title":"Hepatology"},{"issue":"22","key":"pone.0341366.ref039","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.3390\/jcm13226770","article-title":"Beyond the liver: A comprehensive review of strategies to prevent hepatocellular carcinoma","volume":"13","author":"N Polpichai","year":"2024","journal-title":"J Clin Med"},{"key":"pone.0341366.ref040","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.2147\/CMAR.S368366","article-title":"Impact of metabolic dysfunction associated fatty liver disease on the prognosis of patients with hepatitis B Virus-related hepatocellular carcinoma based on propensity score matching analysis","volume":"14","author":"J Xue","year":"2022","journal-title":"Cancer Manag Res"},{"key":"pone.0341366.ref041","article-title":"Impact of components of metabolic syndrome on long-term outcomes of CHB with nucleos(t)ide analogue treatment","author":"R Huang","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"12","key":"pone.0341366.ref042","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.03.024","article-title":"Association between the presence of metabolic comorbidities and liver-related events in patients with chronic hepatitis B","volume":"21","author":"LA Patmore","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"pone.0341366.ref043","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1158\/1055-9965.EPI-19-0303","article-title":"The influence of metabolic syndrome on the risk of hepatocellular carcinoma in patients with chronic hepatitis B infection in Mainland China","volume":"28","author":"Y Tan","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"pone.0341366.ref044","doi-asserted-by":"crossref","first-page":"100350","DOI":"10.1016\/j.jhepr.2021.100350","article-title":"Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B","volume":"3","author":"LA van Kleef","year":"2021","journal-title":"JHEP Rep"},{"key":"pone.0341366.ref045","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/infdis\/jiaa739","article-title":"Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B","volume":"224","author":"J Li","year":"2021","journal-title":"J Infectious Diseases"},{"key":"pone.0341366.ref046","article-title":"Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B","volume":"13","author":"N Uman","year":"2025","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"12","key":"pone.0341366.ref047","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/jvh.13361","article-title":"Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B","volume":"27","author":"S-W Wong","year":"2020","journal-title":"J Viral Hepat"},{"issue":"4","key":"pone.0341366.ref048","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s12072-021-10205-7","article-title":"Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy","volume":"15","author":"JH Oh","year":"2021","journal-title":"Hepatol Int"},{"issue":"23","key":"pone.0341366.ref049","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.3390\/cancers14236012","article-title":"Metabolic-associated fatty liver disease, hepatitis B surface antigen seroclearance, and long-term risk of hepatocellular carcinoma in chronic hepatitis B","volume":"14","author":"M-W Yu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"9","key":"pone.0341366.ref050","doi-asserted-by":"crossref","first-page":"100810","DOI":"10.1016\/j.jhepr.2023.100810","article-title":"Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma","volume":"5","author":"BG Song","year":"2023","journal-title":"JHEP Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:28:03Z","timestamp":1769192883000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341366"}},"subtitle":[],"editor":[{"given":"Samuel O.","family":"Antwi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0341366","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}